Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company ...

Brain drug developer MapLight Therapeutics lost two-thirds of its market value Monday after unveiling clinical trial results that, while positive, raised doubts about whether one of its experimental ...

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a ...

Today, a brief rundown of news involving Capricor Therapeutics and Legend Biotech, as well as updates from AstraZeneca, Outlook Therapeutics and Otsuka Pharmaceutical that you may have missed. On back ...

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...

The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future ...

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...

Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in ...

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions ...

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to ...

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck ...

The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British ...